



Scil Proteins Receives Significant Funding to Strengthen In-House Oncology Program

18. May 2006, Halle (Saale), Germany. Scil Proteins has been awarded a two-year grant of around Euro 850,000 by the Investitionsbank Sachsen-Anhalt, an initiative supporting and sustaining economic development in Germany's local state Saxony-Anhalt. Commenting on the award, Dr. Ulrike Fiedler, Managing Director of Scil Proteins, said "Scil Proteins' Affilin™ technology has significant development potential which the award of this grant will immediately expedite. We envisage this support having a major impact on the continued progress of our cancer programme". The grant backs Scil Proteins' investment in lead identification, *in vitro* validation and first *in vivo* efficacy studies with Affilin™ molecules directed against validated cancer targets.

Development opportunities in cancer therapeutics are enormous, with the four major cancer markets (colorectal, prostate, lung and breast cancer) valued in excess of USD 16 billion in 2005 and the total market projected to grow to USD 53 billion by 2008. Targeted protein-based pharmaceuticals as innovative cancer therapies are expected to make a significant contribution to the more than 10% projected CAGR in this sector. Affilin™ molecules are an ideal source for development of targeted therapies, being small proteins readily engineered for high affinity and specificity to diverse disease targets. Further, novel Affilin™-based drug candidates are rapidly identified through automated screening procedures established and operated by Scil Proteins.

About Scil Proteins:

Scil Proteins GmbH, based in Halle (Saale), Germany, is a biotechnology company focusing on exploiting its proprietary Affilin™ technology to discover, develop and commercialize a new generation of products based on human binding proteins. As well as its commitment to biotherapeutics, Scil Proteins is further engaged in discovery and development of Affilin™ proteins for application in chromatography. Furthermore, the company has internationally recognized expertise in recombinant protein production and industrial process development. This expertise is made available to customers via Scil Proteins Services.

For more information, visit the company's website at <http://www.scilproteins.com>.